Assessing the quality and value of metabolic chart data for capturing core outcomes for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.

Core outcome set Data quality MCAD deficiency

Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
13 Jan 2024
Historique:
received: 19 05 2023
accepted: 27 10 2023
medline: 13 1 2024
pubmed: 13 1 2024
entrez: 12 1 2024
Statut: epublish

Résumé

Generating rigorous evidence to inform care for rare diseases requires reliable, sustainable, and longitudinal measurement of priority outcomes. Having developed a core outcome set for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, we aimed to assess the feasibility of prospective measurement of these core outcomes during routine metabolic clinic visits. We used existing cohort data abstracted from charts of 124 children diagnosed with MCAD deficiency who participated in a Canadian study which collected data from birth to a maximum of 11 years of age to investigate the frequency of clinic visits and quality of metabolic chart data for selected outcomes. We recorded all opportunities to collect outcomes from the medical chart as a function of visit rate to the metabolic clinic, by treatment centre and by child age. We applied a data quality framework to evaluate data based on completeness, conformance, and plausibility for four core MCAD outcomes: emergency department use, fasting time, metabolic decompensation, and death. The frequency of metabolic clinic visits decreased with increasing age, from a rate of 2.8 visits per child per year (95% confidence interval, 2.3-3.3) among infants 2 to 6 months, to 1.0 visit per child per year (95% confidence interval, 0.9-1.2) among those ≥ 5 years of age. Rates of emergency department visits followed anticipated trends by child age. Supplemental findings suggested that some emergency visits occur outside of the metabolic care treatment centre but are not captured. Recommended fasting times were updated relatively infrequently in patients' metabolic charts. Episodes of metabolic decompensation were identifiable but required an operational definition based on acute manifestations most commonly recorded in the metabolic chart. Deaths occurred rarely in these patients and quality of mortality data was not evaluated. Opportunities to record core outcomes at the metabolic clinic occur at least annually for children with MCAD deficiency. Methods to comprehensively capture emergency care received at outside institutions are needed. To reduce substantial heterogeneous recording of core outcome across treatment centres, improved documentation standards are required for recording of recommended fasting times and a consensus definition for metabolic decompensations needs to be developed and implemented.

Sections du résumé

BACKGROUND BACKGROUND
Generating rigorous evidence to inform care for rare diseases requires reliable, sustainable, and longitudinal measurement of priority outcomes. Having developed a core outcome set for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, we aimed to assess the feasibility of prospective measurement of these core outcomes during routine metabolic clinic visits.
METHODS METHODS
We used existing cohort data abstracted from charts of 124 children diagnosed with MCAD deficiency who participated in a Canadian study which collected data from birth to a maximum of 11 years of age to investigate the frequency of clinic visits and quality of metabolic chart data for selected outcomes. We recorded all opportunities to collect outcomes from the medical chart as a function of visit rate to the metabolic clinic, by treatment centre and by child age. We applied a data quality framework to evaluate data based on completeness, conformance, and plausibility for four core MCAD outcomes: emergency department use, fasting time, metabolic decompensation, and death.
RESULTS RESULTS
The frequency of metabolic clinic visits decreased with increasing age, from a rate of 2.8 visits per child per year (95% confidence interval, 2.3-3.3) among infants 2 to 6 months, to 1.0 visit per child per year (95% confidence interval, 0.9-1.2) among those ≥ 5 years of age. Rates of emergency department visits followed anticipated trends by child age. Supplemental findings suggested that some emergency visits occur outside of the metabolic care treatment centre but are not captured. Recommended fasting times were updated relatively infrequently in patients' metabolic charts. Episodes of metabolic decompensation were identifiable but required an operational definition based on acute manifestations most commonly recorded in the metabolic chart. Deaths occurred rarely in these patients and quality of mortality data was not evaluated.
CONCLUSIONS CONCLUSIONS
Opportunities to record core outcomes at the metabolic clinic occur at least annually for children with MCAD deficiency. Methods to comprehensively capture emergency care received at outside institutions are needed. To reduce substantial heterogeneous recording of core outcome across treatment centres, improved documentation standards are required for recording of recommended fasting times and a consensus definition for metabolic decompensations needs to be developed and implemented.

Identifiants

pubmed: 38216926
doi: 10.1186/s12887-023-04393-4
pii: 10.1186/s12887-023-04393-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

37

Subventions

Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195
Organisme : Canadian Institutes of Health Research (CIHR)
ID : TR3-119195

Informations de copyright

© 2024. The Author(s).

Références

Horvath GA, Davidson AGF, Stockler-Ipsiroglu SG, Lillquist YP, Waters PJ, Olpin S, et al. Newborn screening for MCAD deficiency: Experience of the first three years in British Columbia, Canada. Can J Public Heal. 2008;99(4):276–80.
doi: 10.1007/BF03403754
Kennedy S, Potter BK, Wilson K, Fisher L, Geraghty M, Milburn J, et al. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC Pediatr. 2010;10:82.
doi: 10.1186/1471-2431-10-82 pubmed: 21083904 pmcid: 2996355
Zschocke J, Schulze A, Lindner M, Fiesel S, Olgemöller K, Hoffman GF, et al. Molecular and functional characterisation of mild MCAD deficiency. Hum Genet. 2001;108(5):404–8.
doi: 10.1007/s004390100501 pubmed: 11409868
Merritt JL 2nd, Chang IJ. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1424/ . Updated 2019 Jun 27.
Piercy H, Machaczek K, Ali P, Yap S. Parental experiences of raising a child with medium chain Acyl-CoA dehydrogenase deficiency. Glob Qual Nurs Res. 2017;4:2333393617707080.
pubmed: 28516128 pmcid: 5419063
Schatz UA, Ensenauer R. The clinical manifestation of MCAD deficiency: Challenges towards adulthood in the screened population. J Inherit Metab Dis. 2010;33(5):513–20.
doi: 10.1007/s10545-010-9115-5 pubmed: 20532824
Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected children. J Pediatr. 1994;124(3):409–15.
doi: 10.1016/S0022-3476(94)70363-9 pubmed: 8120710
McGregor TL, Berry SA, Dipple KM, Hamid R. Management principles for acute illness in patients with medium-chain acyl-coenzyme a dehydrogenase deficiency. Pediatrics. 2021;147(1): e2020040303.
doi: 10.1542/peds.2020-040303 pubmed: 33372121
Batten W, Chronopoulou E, Pierre G. P37 A single paediatric centre experience of l-carnitine supplementation in medium-chain acyl-coa dehydrogenase deficiency (mcadd). Arch Dis Child. 2018;103: e2.
doi: 10.1136/archdischild-2017-314585.46
Lee PJ, Harrison EL, Jones MG, Jones S, Leonard JV, Chalmers RA. L-Carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: A pilot study. J Inherit Metab Dis. 2005;28(2):141–52.
doi: 10.1007/s10545-005-5262-5 pubmed: 15877203
Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, et al. Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-Carnitine supplementation. J Clin Endocrinol Metab. 2013;98(4):1667–75.
doi: 10.1210/jc.2012-3791 pubmed: 23426616
Potter BK, Little J, Chakraborty P, Kronick JB, Evans J, Frei J, et al. Variability in the clinical management of fatty acid oxidation disorders: Results of a survey of Canadian metabolic physicians. J Inherit Metab Dis. 2012;35(1):115–23.
doi: 10.1007/s10545-011-9352-2 pubmed: 21630065
Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: What are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117–23.
doi: 10.1038/gim.2015.42 pubmed: 25856667
Clarke M, Williamson PR. Core outcome sets and systematic reviews. Syst Rev. 2016;5:11.
doi: 10.1186/s13643-016-0188-6 pubmed: 26792080 pmcid: 4719739
Prinsen CAC, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: Protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a “core outcome set.” Trials. 2014;15:247.
doi: 10.1186/1745-6215-15-247 pubmed: 24962012 pmcid: 4082295
Kodra Y, Weinbach J, Posada-De-La-Paz M, Coi A, Lemonnier SL, van Enckevort D, et al. Recommendations for improving the quality of rare disease registries. Int J Environ Res Public Health. 2018;15(8):1644.
doi: 10.3390/ijerph15081644 pubmed: 30081484 pmcid: 6121483
Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: Version 1.0. Trials. 2017;18(Suppl 3):280.
doi: 10.1186/s13063-017-1978-4 pubmed: 28681707 pmcid: 5499094
Pugliese M, Tingley K, Chow A, Pallone N, Smith M, Rahman A, et al. Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. Orphanet J Rare Dis. 2020;15(1):12.
doi: 10.1186/s13023-019-1276-1 pubmed: 31937333 pmcid: 6961328
Pugliese M, Tingley K, Chow A, Pallone N, Smith M, Chakraborty P, et al. Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. Pediatrics. 2021;148(2): e2020037747.
doi: 10.1542/peds.2020-037747 pubmed: 34266901
Karaceper MD, Khangura SD, Wilson K, Coyle D, Brownell M, Davies C, et al. Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: A cohort study in Ontario, Canada. Orphanet J Rare Dis. 2019;14(1):70.
doi: 10.1186/s13023-019-1001-0 pubmed: 30902101 pmcid: 6431026
Prinsen CAC, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” - a practical guideline. Trials. 2016;17(1):449.
doi: 10.1186/s13063-016-1555-2 pubmed: 27618914 pmcid: 5020549
Tingley K, Lamoureux M, Pugliese M, Geraghty M, Kronick J, Potter B, et al. Evaluation of the quality of clinical data collection for a pan-Canadian cohort of children affected by inherited metabolic diseases: Lessons learned from the Canadian Inherited Metabolic Diseases Research Network. Orphanet J Rare Dis. 2020;15(1):89.
doi: 10.1186/s13023-020-01358-z pubmed: 32276663 pmcid: 7149838
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.
doi: 10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.
doi: 10.1016/j.jbi.2019.103208 pubmed: 31078660 pmcid: 7254481
Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, et al. A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data. eGEMs. 2016;4(1):1244.
doi: 10.13063/2327-9214.1244 pubmed: 27713905 pmcid: 5051581
Derks TGJ, Van Spronsen FJ, Rake JP, Van Der Hilst CS, Span MM, Smit GPA. Safe and unsafe duration of fasting for children with MCAD deficiency. Eur J Pediatr. 2007;166(1):5–11.
doi: 10.1007/s00431-006-0186-0 pubmed: 16788829
McHugh ML. Interrater reliability: The kappa statistic. Biochem Medica. 2012;22(3):276–82.
doi: 10.11613/BM.2012.031
Wang SS. Medium chain acyl-CoA dehydrogenase deficiency: Human genome epidemiology review. Genet Med. 1999;1(7):332–9.
doi: 10.1097/00125817-199911000-00004 pubmed: 11263545
Klose DA, Kölker S, Heinrich B, Prietsch V, Mayatepek E, Von Kries R, et al. Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics. 2002;110(6):1204–11.
doi: 10.1542/peds.110.6.1204 pubmed: 12456920
Dyack S. Expanded newborn screening: Lessons learned from MCAD deficiency. Paediatr Child Health. 2004;9(4):241–3.
doi: 10.1093/pch/9.4.241 pubmed: 19655016 pmcid: 2720504
Derks TGJ, Reijngoud DJ, Waterham HR, Gerver WJM, van den Berg MP, Sauer PJJ, et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: Clinical presentation and outcome. J Pediatr. 2006;148(5):665–70.
doi: 10.1016/j.jpeds.2005.12.028 pubmed: 16737882
Allori AC, Kelley T, Meara JG, Albert A, Bonanthaya K, Chapman K, et al. A standard set of outcome measures for the comprehensive appraisal of cleft care. Cleft Palate Craniofac J. 2017;54(5):540–54.
doi: 10.1597/15-292 pubmed: 27223626
Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update. Genet Med. 2006;8(4):205–12.
doi: 10.1097/01.gim.0000204472.25153.8d pubmed: 16617240
Pan L, Fergusson D, Schweitzer I, Hebert PC. Ensuring high accuracy of data abstracted from patient charts: The use of a standardized medical record as a training tool. J Clin Epidemiol. 2005;58(9):918–23.
doi: 10.1016/j.jclinepi.2005.02.004 pubmed: 16085195

Auteurs

Ryan Iverson (R)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Monica Taljaard (M)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.

Michael T Geraghty (MT)

Department of Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada.

Michael Pugliese (M)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Kylie Tingley (K)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Doug Coyle (D)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Jonathan B Kronick (JB)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Kumanan Wilson (K)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Bruyère Research Institute, Ottawa, Canada.
Department of Medicine, University of Ottawa, Ottawa, Canada.

Valerie Austin (V)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Catherine Brunel-Guitton (C)

Le Centre Hospitalier Universitaire Ste-Justine, Montreal, Canada.

Daniela Buhas (D)

McGill University Health Centre, Montreal, Canada.

Nancy J Butcher (NJ)

The Hospital for Sick Children Research Institute/University of Toronto, Toronto, Canada.

Alicia K J Chan (AKJ)

Department of Medical Genetics, University of Alberta/Stollery Children's Hospital, Edmonton, Canada.

Sarah Dyack (S)

IWK Health Centre/Dalhousie University, Halifax, Canada.

Sharan Goobie (S)

IWK Health Centre/Dalhousie University, Halifax, Canada.

Cheryl R Greenberg (CR)

Health Sciences Centre Winnipeg/University of Manitoba, Winnipeg, Canada.

Shailly Jain-Ghai (S)

Department of Medical Genetics, University of Alberta/Stollery Children's Hospital, Edmonton, Canada.

Michal Inbar-Feigenberg (M)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Natalya Karp (N)

London Health Sciences Centre/Western University, London, Canada.

Mariya Kozenko (M)

McMaster Children's Hospital, Hamilton, Canada.

Erica Langley (E)

Department of Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada.

Matthew Lines (M)

Hamilton Health Sciences Centre/McMaster University, Hamilton, Canada.

Julian Little (J)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Jennifer MacKenzie (J)

McMaster Children's Hospital, Hamilton, Canada.
Janeway Children's Hospital/Memorial University, St John's, Canada.

Bruno Maranda (B)

CIUSSSE-CHUS, Université de Sherbrooke, Sherbrooke, Canada, Sherbrooke, Canada.

Saadet Mercimek-Andrews (S)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Aizeddin Mhanni (A)

Health Sciences Centre Winnipeg/University of Manitoba, Winnipeg, Canada.

John J Mitchell (JJ)

McGill University Health Centre, Montreal, Canada.

Laura Nagy (L)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Martin Offringa (M)

The Hospital for Sick Children Research Institute/University of Toronto, Toronto, Canada.

Amy Pender (A)

McMaster Children's Hospital, Hamilton, Canada.

Murray Potter (M)

McMaster Children's Hospital, Hamilton, Canada.

Chitra Prasad (C)

London Health Sciences Centre/Western University, London, Canada.

Suzanne Ratko (S)

London Health Sciences Centre/Western University, London, Canada.

Ramona Salvarinova (R)

BC Children's Hospital/University of British Columbia, Vancouver, Canada.

Andreas Schulze (A)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Komudi Siriwardena (K)

Department of Medical Genetics, University of Alberta/Stollery Children's Hospital, Edmonton, Canada.

Neal Sondheimer (N)

The Hospital for Sick Children/University of Toronto, Toronto, Canada.

Rebecca Sparkes (R)

Alberta Children's Hospital/University of Calgary, Calgary, Canada.

Sylvia Stockler-Ipsiroglu (S)

BC Children's Hospital/University of British Columbia, Vancouver, Canada.

Kendra Tapscott (K)

BC Children's Hospital/University of British Columbia, Vancouver, Canada.

Yannis Trakadis (Y)

McGill University Health Centre, Montreal, Canada.

Lesley Turner (L)

Janeway Children's Hospital/Memorial University, St John's, Canada.

Clara Van Karnebeek (C)

BC Children's Hospital/University of British Columbia, Vancouver, Canada.
Emma Center for Personalized Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Anthony Vandersteen (A)

IWK Health Centre/Dalhousie University, Halifax, Canada.

Jagdeep S Walia (JS)

Kingston Health Sciences/Queen's University, Kingston, Canada.

Brenda J Wilson (BJ)

Janeway Children's Hospital/Memorial University, St John's, Canada.

Andrea C Yu (AC)

Department of Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada.

Beth K Potter (BK)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Pranesh Chakraborty (P)

Department of Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, 401 Smyth Road, Ottawa, ON, K1H 8L1, Canada. pchakraborty@cheo.on.ca.
Newborn Screening Ontario, Ottawa, Canada. pchakraborty@cheo.on.ca.

Classifications MeSH